The term diabetes type 3 has been used in relation to Alzheimer’s disease, by scientists. In recent years there have been important advances in the understanding of the pathogenesis of Alzheimer disease. It is now a well-established fact that the principal cause of Alzheimer disease is excessive deposition of the protein beta-amyloid  in the brain. The excess beta-amyloid forms “plaques” which surround nerve cells in the brain, stopping them from working properly in the brain.
Normally, excess beta-amyloid is removed by a series of proteolytic enzymes. It has now been found that the most effective beta-amyloid removing proteolytic enzyme is neprolysin . Unfortunately, the activity of neprolysin declines with age. Its activity has been found to be reduced in the brains of Alzheimer sufferers .
As neprolysin activation has already been proposed as an alternative approach to the resolution of and protection against Alzheimer disease, a new sequence-specific homeopathic DNA (SSHD) remedy has been developed to target the MME gene as this is the gene that encodes the enzyme neprolysin.
Alzheimer disease is also referred to as type 3 diabetes . Insulin plays an important role in brain function. Alzheimer disease is also associated with insulin resistance . Therefore, to help the insulin receptor work better, this remedy has been designed to also target the PPARG gene because the product of this gene plays an important role in preserving the function of the insulin receptor .
Hence in the light of the above scientific data, there is enough evidence that upregulation of genes MME and PPARG help resolve and delay the onset of Alzheimer disease. The SSHD-MME/PPG molecules promote the function of genes MME and PPARG.
- Tyagi S et al., The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J. Adv. Pharm. Technol. Res. 2011:2;